Monitor commercial launch cadence and initial TCAR procedure adoption in coming quarters. The CGUARDIANS III trial enrollment progress for SwitchGuard NPS will determine whether InspireMD can offer a fully integrated proprietary platform, which could further expand per-procedure revenue capture.
NSPR drugs
NSPR drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 13 $0.6441entry
- T+1 · yesterday −6.85%α −4.94% · $0.6000
- T+2 · todayOpen
- T+5 · in 3d Pending
- T+20 · in 27d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
InspireMD announced FDA approval of its CGuard Prime TransCarotid Stent System for use in TCAR procedures, doubling the platform's U.S. addressable market to approximately 75,000 annual carotid stenting procedures. The approval is supported by CGUARDIANS II pivotal trial data showing 100% acute device success and zero adverse events at 30 days.
Key Facts
- FDA approved PMA Supplement for CGuard Prime TransCarotid Stent System for TCAR procedures on November 12, 2026.
- Approval doubles CGuard Prime platform's total addressable market in the U.S. with access to over 35,000 TCAR procedures annually.
- TCAR and CAS together represent approximately 75,000 annual carotid stenting procedures in the U.S. per company estimates.
- CGUARDIANS II pivotal trial enrolled 50 patients across 11 sites; at 30 days, 100% acute device success with zero deaths, strokes, myocardial infarctions, or stent thrombosis.
- CGuard Prime TransCarotid Stent System features an 80 cm delivery system and proprietary MicroNet technology.
- Company is first to offer both CAS and TCAR delivery options for carotid revascularization.
- SwitchGuard NPS (investigational) is being evaluated in CGUARDIANS III pivotal trial currently enrolling.
Financial Impact
Doubles addressable market from CAS-only to CAS+TCAR, adding over 35,000 annual procedures; no specific revenue or financial figures provided.
Risk Factors
- Company faces a voluntary U.S. recall of the CGuard Prime 135 cm delivery system, with associated costs and potential customer/patient claims.
- History of recurring losses, negative cash flows, and substantial doubt about going concern; may need additional capital that could dilute shareholders.
- SwitchGuard NPS is investigational and not yet FDA-cleared; TCAR market entry currently depends on using a third-party embolic protection system.
- Intense competition from larger, better-capitalized medical device companies.
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-051453 |
| Exhibit: ex99-1.htm | 0001493152-26-051453 |
| Document: 0001493152-26-051453-index-headers.html | 0001493152-26-051453 |
| Document: 0001493152-26-051453-index.html | 0001493152-26-051453 |
| Document: 0001493152-26-051453.txt | 0001493152-26-051453 |
Track record
29 reports on NSPR
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +54.19% at T+60 after the Apr 3, 2026 report. 10 of 13 went positive at some point.
Filters
- Nov 17, 2026today Insider Cluster Mixed 5/10 Entry $0.6500 Now $0.6500 −0.00% settles Feb 17
- Nov 16, 20261d ago 8-K Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 12
- Nov 16, 20261d ago 424B5 Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 12
- Nov 13, 20264d ago Press Release Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
- Nov 12, 20264d ago 424B5 Bearish 6/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
- Nov 12, 20264d ago 8-K Bullish 7/10 No price data
- Nov 12, 20264d ago 8-K Bullish 6/10 Viewing Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
- Nov 12, 20265d ago Press Release Bearish 5/10 Entry $0.6441 Now $0.6500 −0.92% settles Feb 11
- Nov 12, 20265d ago Press Release Bullish 7/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
- Nov 12, 20265d ago Press Release Bullish 8/10 Entry $0.6441 Now $0.6500 +0.92% settles Feb 11
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers